

Angelica Corral Garcia Heras

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/698/publications.pdf>

Version: 2024-02-01

37
papers

1,015
citations

393982

19
h-index

414034

32
g-index

37
all docs

37
docs citations

37
times ranked

1191
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma Levels of Atazanavir and the Risk of Hyperbilirubinemia Are Predicted by the 3435C->T Polymorphism at the Multidrug Resistance Gene 1. <i>Clinical Infectious Diseases</i> , 2006, 42, 291-295.	2.9	116
2	High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. <i>Aids</i> , 2007, 21, 2503-2511.	1.0	66
3	Correlation between Human Immunodeficiency Virus Type 1 (HIV-1) RNA Measurements Obtained with Dried Blood Spots and Those Obtained with Plasma by Use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV Load Tests. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1031-1036.	1.8	66
4	Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 885-888.	1.3	54
5	Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors and Prevalence of HIV Type 1 Non-B Subtypes Are Increasing among Persons with Recent Infection in Spain. <i>Clinical Infectious Diseases</i> , 2005, 41, 1350-1354.	2.9	53
6	Risk of selecting K65R in antiretroviral-naïve HIV-infected individuals with chronic hepatitis B treated with adefovir. <i>Aids</i> , 2005, 19, 2036-2038.	1.0	46
7	Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. <i>Journal of Medical Virology</i> , 2007, 79, 1040-1046.	2.5	43
8	Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. <i>Aids</i> , 2008, 22, 611-616.	1.0	37
9	Predictors of selection of K65R. <i>Aids</i> , 2004, 18, 2094-2096.	1.0	36
10	Changing Rates and Patterns of Drug Resistance Mutations in Antiretroviral-Experienced HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 879-885.	0.5	35
11	High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor. <i>Aids</i> , 2010, 24, 467-469.	1.0	34
12	Changes in the Human Immunodeficiency Virus p7-p1-p6 gag Gene in Drug-Naïve and Pretreated Patients. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1245-1247.	1.8	33
13	Preparation and Characterization of Antimicrobial Films Based on LDPE/Ag Nanoparticles with Potential Uses in Food and Health Industries. <i>Nanomaterials</i> , 2018, 8, 60.	1.9	33
14	Evidence for Differences in the Sexual Transmission Efficiency of HIV Strains with Distinct Drug Resistance Genotypes. <i>Clinical Infectious Diseases</i> , 2004, 39, 1231-1238.	2.9	32
15	Antiretroviral Recommendations May Influence the Rate of Transmission of Drug-Resistant HIV Type 1. <i>Clinical Infectious Diseases</i> , 2005, 41, 227-232.	2.9	31
16	Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 1409-1410.	1.3	31
17	Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance. <i>Aids</i> , 2006, 20, 1071-1074.	1.0	29
18	Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Madrid. <i>Aids</i> , 2002, 16, 1830-1832.	1.0	26

#	ARTICLE	IF	CITATIONS
19	Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals. <i>Journal of Virological Methods</i> , 2004, 121, 115-118.	1.0	25
20	Short Communication:Prevalence of G333D/E in Naive and Pretreated HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 857-860.	0.5	19
21	Changing Patterns in HIV Reverse Transcriptase Resistance Mutations after Availability of Tenofovir. <i>Clinical Infectious Diseases</i> , 2008, 46, 1782-1785.	2.9	19
22	Short Communication High Risk of Endothelial Dysfunction in HIV Individuals May Result from Deregulation of Circulating Endothelial Cells and Endothelial Progenitor Cells. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 656-659.	0.5	17
23	Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations. <i>Aids</i> , 2004, 18, 2091-2094.	1.0	16
24	Changes in Drug Resistance Patterns following the Introduction of HIV Type 1 Non-B Subtypes in Spain. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 967-972.	0.5	14
25	Indinavir Plasma Concentrations and Resistance Mutations in Patients Experiencing Early Virological Failure. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 457-459.	0.5	13
26	Fibrous nanocomposites based on EVA40 filled with Cu nanoparticles and their potential antibacterial action. <i>Materials Today Communications</i> , 2019, 20, 100581.	0.9	13
27	Photoswitching-Enabled Contrast Enhancement in Light Sheet Fluorescence Microscopy. <i>ACS Photonics</i> , 2017, 4, 424-428.	3.2	12
28	PCL/collagen blends prepared by solution blow spinning as potential materials for skin regeneration. <i>Journal of Applied Polymer Science</i> , 2021, 138, 50493.	1.3	10
29	Minority HIV mutation detection in dried blood spots indicates high specimen integrity and reveals hidden archived drug resistance. <i>Journal of Clinical Virology</i> , 2011, 50, 148-152.	1.6	9
30	Prevalence of Novel Lamivudine-Resistant Genotypes (E44D/A, V118I) in Naive and Pretreated HIV-Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000, 25, 95-96.	0.9	8
31	Relationship between drug resistance mutations, plasma viremia, and CD4+T-cell counts in patients with chronic HIV infection. <i>Journal of Medical Virology</i> , 2005, 76, 1-6.	2.5	8
32	Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance. <i>Aids</i> , 2008, 22, 311-313.	1.0	8
33	Use of Different Inhibitory Quotients To Predict Early Virological Response to Tipranavir in Antiretroviral-Experienced Human Immunodeficiency Virus-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4153-4158.	1.4	6
34	Estimated Extent of Cross-Resistance to Ritonavir-Boosted Protease Inhibitors Among Protease Inhibitors-Experienced Patients: Implications for Tipranavir Use. <i>AIDS Patient Care and STDs</i> , 2005, 19, 67-69.	1.1	5
35	Prevalence of the HIV Protease Mutation N88S Causing Hypersensitivity to Amprenavir. <i>Clinical Infectious Diseases</i> , 2002, 34, 1288-1289.	2.9	4
36	Prevalence of drug resistance genotypes causing broad cross-resistance to nucleos(t)ide analogues. <i>Aids</i> , 2004, 18, 689-690.	1.0	4

#	ARTICLE	IF	CITATIONS
37	Low rate of HIV-1 codon 215 revertants in antiretroviral-experienced patients. <i>Aids</i> , 2003, 17, 919-921.	1.0	4